Revvity Inc 2025年度报告

2025 Annual Report We are helpingØùƃØĸóýǹŪĘýǹLJşţŪǹıØşđýțţóØıýǹĸýƄòŁşĸǹđýĸŁķýǹţóşýýĸěĸđǹěĸěŪěØŪěƃýǹŁĐǹěŪţǹĮěĸùǿ Dear Shareholders, As I look back on 2025, I am struck by the extraordinary moment we find ourselves in, one wherescience, technology, and human potential are converging in ways few could have imagined even adecade ago. At Revvity, we are embracing this inflection point with purpose and optimism, confident inour ability to help shape a future where disease is detected earlier, therapies are discovered faster, andhealth outcomes are improved for people everywhere. This year, artificial intelligence became an even more integral part of how we operate and how ourcustomers innovate. AI is no longer an enhancement; it is a new foundation for scientific progress. Wedeployed next-generation AI tools across our global workforce, empowering teams to work morecreatively and efficiently. And with solutions like the Signals Xynthetica platform, we are bringing thepower of predictive science directly into the daily workflows of researchers. When these models arepaired with real experimental data, the pace of discovery accelerates and the possibilities expand. Across our Diagnostics business, we are also harnessing AI to enhance accuracy in early diseasedetection, reduce time-to-diagnosis, and support more informed clinical decision-making. Fromreproductive health and newborn screening to infectiousdisease testing, AI-driven insights are helping providersidentify risk earlier, intervene sooner, and ultimatelyimprove patient outcomes. 2025 was also a year in which our company’s leadershipand innovation were on full display – not just as a vendor,but as a strategic partner to our customers. Throughour expanded partnership with Genomics England,we are helping advance the first large-scale newborngenome screening initiative of its kind. With Sanofi, we areenabling population-scale screening for Type 1 diabetesrisk, an advancement that has the potential to change thetrajectory of a lifelong disease. Revvity employees attend ribbon cutting atGenomics England (UK) lab. These efforts remind us that when innovationmeets intention, science can transform livesin powerful ways. Across Revvity, our teamscontinued to push the boundaries of what’spossible in other areas as well. We receivedFDA approval for a new automated solutionfor latent tuberculosis detection, supportingthe global fight against one of the world’s mostpersistent infectious diseases. We openedourIn VivoImaging Center of Excellence, aplace where the next generation of imagingtechnologies is already taking shape. And Revvity employees celebrate opening of theIn VivoImaging Centerof Excellence (NC, USA). we further strengthened our portfolio and customer solutionsthrough ongoing innovation, enabling us to deliver durable, high-quality growth while advancing our purpose. “Revvity is built for thismoment, powered by atransformed portfolio, guidedby a clear purpose, and unitedby a belief that science canimprove lives in ways we areonly beginning to imagine.” Our vision also extends to the way we operate. In 2025, wemade meaningful progress toward our sustainability goals byreducing emissions, surpassing our waste diversion target twoyears ahead of schedule, and earning an AAA ESG rating frominvestment research firm MSCI. We also recognize that peopleare the driving force behind scientific breakthroughs. That’s whyin 2025 we expanded the Revvity Access STEM Scholarshipsto help cultivate the next generation of scientific leaders andinvested in initiatives to strengthen our workplace environmentand employee experience. Reflecting this high-trust, employee-focused approach, Revvity was recognized globally as a GreatPlace to Work®. Prahlad Singh, PhDPresident and CEO„ýƃƃěŪƊȀǺDĸóǿ Looking ahead, I am more inspired than ever by the work wedo and the impact we can make. The distance between earlydiscovery and clinical care is shrinking. The complexity ofdisease biology is giving rise to new opportunities for precisionmedicine. And AI is redefining the boundaries of speed, insight,and possibility. Revvity is built for this moment, powered by atransformed portfolio, guided by a clear purpose, and unitedby a belief that science can improve lives in ways we are onlybeginning to imagine. Thank you for your continued trust and partnership. Together,we are building not only a stronger company, but a brighter andhealthier future for generations to come. Regards, Prahlad Corporate Governance Board of Directors Corporate Officers Prahlad Singh, PhDPresident and Chief Executive OfficerRevvity, Inc. Prahlad Singh, PhDPresident and Chief Executive Officer Joel S. GoldbergSenior Vice President,Administration, GeneralCounsel and Secretary Peter Barrett, PhDPartnerAtlas Venture Samuel R. ChapinRetired Executive Vice ChairmanBank of America Merrill Lynch Max KrakowiakSenior Vice President andChief Financial Officer Michael A. KlobucharChief Operating OfficerEiko